Evidence-based analysis, vendor accountability, and honest guidance in a market flooded with marketing claims.
The FDA advisory committee reviews 7 peptides July 23-24. Meanwhile the first real BPC-157 human trial begins and semaglutide fails in Alzheimer's.
12 peptides came off Category 2 in April, but June brought a stacked FDA advisory panel, agency scientists warning against approval, and new warning letters.
Independent analysis of the FDA peptide reclassification. 12 peptides came off Category 2 in April. The July 23-24 PCAC vote decides what happens next.
FDA still hasn't published peptide reclassification 29 days after RFK announcement. NPR coverage drives new audience. SAFE Drugs Act bill text on Congress.gov.
Independent guide to buying BPC-157 in 2026. Grey-market vendors rated, compounding pharmacy options, and what the FDA reclassification means for access.
Guide to legal semaglutide access in 2026. FDA-approved Ozempic, Wegovy, Oral Wegovy ($149/mo), and why grey-market semaglutide should be avoided.
Complete guide to buying peptides in 2026. Grey-market vendors rated, compounding pharmacy pathways, telehealth options, and what the reclassification means.
Peptide Sciences shuts down. The FDA still hasn't published reclassification. The SAFE Drugs Act threatens the RUO model.
Analysis of why Peptide Sciences shut down on March 6, 2026. FDA enforcement, Big Pharma litigation, and quality failures ended the grey-market era.
Deep analysis of CJC-1295 and ipamorelin — the most used GH secretagogue stack. Mechanism, evidence gaps, and what community protocols actually rest on.
RFK Jr. announces reclassification of 14 Category 2 peptides on Joe Rogan. Hims & Hers confirms peptide line. HIMS stock surges.
Monthly roundup: MIT Technology Review's peptide feature, RFK Jr.'s FDA influence, Chinese import crackdown, and regulatory uncertainty.
Evidence-based analysis of sermorelin + testosterone therapy. What studies show about GH-testosterone synergy and body composition.
Timeline of FDA enforcement actions against peptide vendors from 2023-2026: warning letters, criminal cases, and regulatory changes.
Complete timeline of FDA and ITC enforcement actions against peptide vendors from 2024-2026. Warning letters, exclusion orders, and the BPC-157 ban.
New to peptides? Our beginner's guide covers what peptides are, how to evaluate vendors, safety considerations, and what to know first.
Analysis of independent testing data revealing alarming quality failures in grey-market peptides. What Finnrick, Janoshik, and other labs have found.
Independent deep dive into Infiniwell's SNAC-enhanced BPC-157 products. We examine the technology claims, the missing studies, and what consumers should know.
Learn which peptides have genuine oral bioavailability and which don't. Science-based guide to absorption technologies like SNAC and liposomes.
Analysis of Pentadeca Arginate (PDA) claims: the patent, the chemistry, and the missing evidence behind '99% bioavailability' marketing.
How semaglutide went from pharmaceutical breakthrough to public health crisis. The compounding controversy, counterfeit risks, and what consumers need to know.
Critical analysis of TB-500 vs. Thymosin Beta-4. The research uses one molecule; the market sells another. We examine what the evidence actually supports.
An evidence-based analysis of oral BPC-157 bioavailability claims. We examine what the research actually shows versus what vendors tell you.
Analysis of the FDA's September 2025 enforcement wave: 50+ warning letters to peptide and GLP-1 compounders in a single month.
Learn to evaluate peptide COAs: what each test means, red flags for fake documentation, and which labs are considered credible.